NCT00946699 - A Study of the Safety and Tolerability of MEDI-551 in Scleroderma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2014

Conditions

Scleroderma

Interventions

BIOLOGICAL

MEDI-551

0.1 mg/kg

BIOLOGICAL

Placebo

0.3 mg/kg

BIOLOGICAL

MEDI-551

1.0 mg/kg

BIOLOGICAL

MEDI-551

3.0 mg/kg

BIOLOGICAL

MEDI-551

10.0 mg/kg

OTHER

Placebo

Trial Locations (14)

Research Site, Loma Linda

Research Site, Redwood City

Research Site, Farmington

Research Site, Shreveport

Research Site, Worcester

Research Site, Ann Arbor

Research Site, New Brunswick

Research Site, Great Neck

Research Site, Durham

Research Site, Cleveland

Research Site, Duncansville

Research Site, Dallas

Research Site, Winnipeg

Research Site, London